Respiratory tract deposition of 99mTc-labelled drug particles administered via a dry powder inhaler

Vidgrén, M.; Kärkkäinen, Anna‐Mari; Paronen, T.P.; Karjalainen, Panu

doi:10.1016/0378-5173(87)90203-1

Cited by 21 publications

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hence the rationale for the design of the in-vitro test is an attempt to simulate patient use as far as practicable with the hope of achieving correlation of the results obtained from such tests with performance in-vivo. However, previous studies have claimed a poor correlation between in-vitro and in-vivo test results for drugs administered by a DPI (Vidgren et al 1987;Pitcairn et al 1994). In an attempt to improve the correlation between such data, previous work-…”

mentioning

confidence: 99%

A Human Oral-throat Cast Integrated with a Twin-stage Impinger for Evaluation of Dry Powder Inhalers

Srichana

Martin

Marriott

2000

Journal of Pharmacy and Pharmacology

View full text Add to dashboard Cite

The aim of this study was to investigate the applicability of replacing the glass throat from a twin-stage impinger (TSI) with a human oral-throat cast. Monodisperse aerosols were used to calibrate the human oral cast-TSI at 60 L min(-1) and cut-off in particle size was compared with that of the TSI described in the British Pharmacopoeia which employs a glass throat. The amount of salbutamol sulphate (and lactose) delivered by the Cyclohaler depositing on various elements of the in-vitro model were determined. The calibration of the model containing a human oral-throat cast at 60 L min(-1) gave a particle size cut-off of 5.2 microm which was less than that of the TSI (6.3 microm). The oral-throat cast trapped more drug than the glass throat model with a formulation that employed the larger carrier (63-90 microm; P<0.05) while it trapped a lesser amount of drug with those filled with the lower size carrier (Lactochem, micronised lactose). The greater amount of lactose in the formulation that employed the larger-sized carrier (63-90 microm) was deposited closer to the inlet of the oral-throat cast than to the inlet of the glass throat model. Replacement of the glass throat in the TSI by the human oral-throat cast, leads to a change in deposition efficiency, with the cast having a higher filter efficiency and hence more aerosol particles being captured before their entry into the TSI. This should be investigated further to determine whether such a model might provide a more realistic assessment of the in-vivo characteristics of an aerosol in comparison with the TSI currently being employed, which utilises the glass throat as the portal of entry.

show abstract

mentioning

confidence: 99%

A Human Oral-throat Cast Integrated with a Twin-stage Impinger for Evaluation of Dry Powder Inhalers

Srichana

Martin

Marriott

2000

Journal of Pharmacy and Pharmacology

View full text Add to dashboard Cite

show abstract

Safety Assessment of Inhalant and Dermal Route Drugs

2010

Drug Safety Evaluation

View full text Add to dashboard Cite

Safety Assessment of Inhalant and Dermal Route Drugs

2010

Pharmaceutical Sciences Encyclopedia

View full text Add to dashboard Cite

The two common routes for administering a drug are inhalation and dermally. As administration of inhalants and dermal route drugs may result in adverse local and/or systemic effects, safety assessment of drugs with respect to the therapeutic‐to‐toxicity ratio are essential. This article focuses on both regulatory and technological considerations for safety assessment of inhalants and dermal route drugs.

show abstract

Respiratory tract deposition of 99mTc-labelled drug particles administered via a dry powder inhaler

Cited by 21 publications

References 16 publications

A Human Oral-throat Cast Integrated with a Twin-stage Impinger for Evaluation of Dry Powder Inhalers

A Human Oral-throat Cast Integrated with a Twin-stage Impinger for Evaluation of Dry Powder Inhalers

Safety Assessment of Inhalant and Dermal Route Drugs

Safety Assessment of Inhalant and Dermal Route Drugs

Contact Info

Product

Resources

About